CSTL logo

CSTL
Castle Biosciences Inc

1,001
Mkt Cap
$741.04M
Volume
341,351.00
52W High
$44.28
52W Low
$14.59
PE Ratio
-28.87
CSTL Fundamentals
Price
$24.46
Prev Close
$23.69
Open
$23.59
50D MA
$26.61
Beta
1.01
Avg. Volume
360,459.61
EPS (Annual)
-$0.8334
P/B
1.54
Rev/Employee
$389,840.32
$865.07
Loading...
Loading...
News
all
press releases
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down on Insider Selling
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down After Insider Selling...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Castle Biosciences (NASDAQ:CSTL) Insider Sells $90,912.20 in Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 3,622 shares of the stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of...
MarketBeat·3d ago
News Placeholder
Castle Biosciences to Present New Data Demonstrating DecisionDx-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Castle Biosciences to Present New Data Demonstrating DecisionDx-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS...
PR Newswire·5d ago
News Placeholder
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat...
MarketBeat·10d ago
News Placeholder
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on...
PR Newswire·11d ago
News Placeholder
Castle Biosciences (NASDAQ:CSTL) Shares Down 7% - What's Next?
Castle Biosciences (NASDAQ:CSTL) Trading Down 7% - What's Next...
MarketBeat·16d ago
News Placeholder
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year PR Newswire FRIENDSWOOD, Texas, April 10, 2026 FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc...
PR Newswire·16d ago
News Placeholder
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 6,214 shares of the company's stock in a transaction dated Monday, April 6th. The stock was sold at an average...
MarketBeat·18d ago
News Placeholder
Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at...
PR Newswire·1mo ago
News Placeholder
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk
Castle Biosciences (NASDAQ:CSTL) executives and clinical collaborators used a DecisionDx-Melanoma webcast to review results from the multicenter DECIDE study, which the company said was recently published in Future Oncology. The discussion focused on how the company's 31-gene expression profile (31...
MarketBeat·1mo ago
<
1
2
...
>

Latest CSTL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.